Main menu

NEW YORK (GenomeWeb News) – Myriad Genetics today said that it has received approval to file an application transferring its shares from the Nasdaq stock exchange to the New York Stock Exchange.

The Salt Lake City-based developer of molecular diagnostics and therapeutics said that it expects to be trading on the NYSE Big Board in the second quarter of 2009. Once the transfer is complete, Myriad will trade under the symbol MGX.